Dicyclomine Side Effects
Medically reviewed by Drugs.com. Last updated on Jun 21, 2023.
Applies to dicyclomine: oral capsules and tablets, oral solution, parenteral injection.
Side effects include:
Most adverse effects are manifestations of pharmacologic effects at muscarinic-cholinergic receptors and usually are reversible when therapy is discontinued.
Severity and frequency of adverse effects are dose related and individual intolerance varies greatly; although adverse effects occasionally may be obviated by a reduction in dosage, this also will likely eliminate potential therapeutic effects. If dosage of ≥80 mg daily cannnot be achieved because of intolerance, discontinue dicyclomine.
Dry mouth, dizziness, blurred vision, nausea, light-headedness (especially with the injectable form), drowsiness, weakness, nervousness.
For Healthcare Professionals
Applies to dicyclomine: compounding powder, intramuscular solution, oral capsule, oral syrup, oral tablet.
General
-The most serious adverse reactions include cardiovascular and central nervous system symptoms.
-The most common adverse reactions are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness, fever, tachycardia, agitation, and dry skin/mucous membranes.[Ref]
Gastrointestinal
Very common (10% or more): Dry mouth (33%), nausea (14%)
Rare (less than 0.1%): Constipation, anorexia
Frequency not reported: Thirst, delayed gastric emptying time, reduced gastric acid secretion, gastroesophageal reflux
Postmarketing reports: Abdominal distension, abdominal pain, dyspepsia, constipation, dry mouth, nausea, vomiting[Ref]
Nervous system
Very common (10% or more): Dizziness (40%)
Common (1% to 10%): Somnolence, nervousness
Rare (less than 0.1%): Sedation, headache
Postmarketing reports: Dizziness, headache, somnolence, syncope[Ref]
Ocular
Very common (10% or more): Blurred vision (27%)
Frequency not reported: Follicular conjunctivitis, all muscarinic antagonists can precipitate glaucoma
Postmarketing reports: Cycloplegia, mydriasis, blurred vision[Ref]
Other
Common (1% to 10%): Asthenia
Frequency not reported: Fatigue
Postmarketing reports: Malaise, fatigue[Ref]
Dermatologic
Rare (less than 0.1%): Rash
Postmarketing reports: Allergic dermatitis, erythema, rash[Ref]
Renal
Rare (less than 0.1%): Dysuria[Ref]
Genitourinary
Frequency not reported: Urinary retention, impotence in male patients
Postmarketing reports: Suppressed lactation[Ref]
Cardiovascular
Postmarketing reports: Palpitations, tachyarrhythmias, thrombosis, thrombophlebitis[Ref]
Hypersensitivity
Postmarketing reports: Face edema, angioedema, anaphylactic shock[Ref]
Local
Postmarketing reports: Local pain, edema, skin color change, reflex sympathetic dystrophy syndrome (caused by inadvertent IV injection)[Ref]
Psychiatric
Postmarketing reports: Delirium or symptoms of delirium such as amnesia (or transient global amnesia), nervousness, agitation, confusional state, delusion, disorientation, hallucination (including visual hallucination), and mania, mood (altered and pseudodementia).[Ref]
Respiratory
Postmarketing reports: Dyspnea, nasal congestion[Ref]
More about dicyclomine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (288)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: anticholinergics/antispasmodics
- Breastfeeding
- En español
Patient resources
- Dicyclomine drug information
- Dicyclomine Capsules and Tablets
- Dicyclomine Injection
- Dicyclomine Syrup and Oral Solution
Other brands
Professional resources
Related treatment guides
References
1. Kagan G, Huddlestone L, Wolstencroft P. Comparison of dicyclomine with antacid and without antacid in dyspepsia. J Int Med Res. 1984;12:174-8.
2. Product Information. Bentyl (dicyclomine). Aventis Pharmaceuticals. 2002.
3. Cerner Multum, Inc. UK Summary of Product Characteristics.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.